{"product_id":"biolegend-505822","title":"Biolegend, 505822, PerCP\/Cyanine5.5 anti-mouse IFN-γ Antibody, 100μg","description":"\u003cp\u003eIFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: E. coli-expressed, recombinant mouse IFN-γ\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PerCP\/Cyanine5.5 under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/mL\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.125 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. * PerCP\/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702\/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)\u003cbr\u003e\nProduct Citations: Li X, et al. 2023. J Clin Invest. 133:. PubMed Giampaolo S, et al. 2023. iScience. 26:106234. PubMed Bhaskar A, et al. 2023. iScience. 26:106644. PubMed Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Wang W, et al. 2022. Cell Rep. 41:111582. PubMed Xie Z, et al. 2022. Cell Discov. 8:133. PubMed Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed Ding L, et al. 2023. J Clin Invest. 133: . PubMed Zhang W, et al. 2022. Front Cell Dev Biol. 10:842813. PubMed Lee Y, et al. 2020. J Innate Immun. 1:. PubMed Chen H, et al. 2005. J Immunol. 175:591. PubMed Li Q, et al. 2022. Cell Rep. 40:111308. PubMed Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed Volkov A, et al. 2013. PLoS One. 8:60565. PubMed Luo Z, et al. 2020. Front Immunol. 0.883333333. PubMed Li B, et al. 2015. Sci Rep. 5: 14793. PubMed Braun F, et al. 2015. PLoS One. 10: 0135444. PubMed Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed Liao T, et al. 2017. Front Immunol. 8:1334. PubMed Coe D, et al. 2022. JCI Insight. 7:. PubMed Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed Carty S, et al. 2014. PLoS One. 9:106659. PubMed Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed He Y, et al. 2017. J Autoimmun. 10.1016\/j.jaut.2017.04.001. PubMed Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed Li X, et al. 2016. MBio. 7: 02232-15. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed Sun Y, et al. 2020. J Immunol. 205:2649. PubMed Burger ML, et al. 2021. Cell. 184:4996. PubMed Wu R, et al. 2020. J Immunother Cancer. 8:00. PubMed Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed\u003cbr\u003e\nRRID: AB_961361 (BioLegend Cat. No. 505821) AB_961359 (BioLegend Cat. No. 505822)\u003cbr\u003e\nStructure: Cytokine; dimer; 40-80 kD (Mammalian)\u003cbr\u003e\nBioactivity: Antiviral\/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.\u003cbr\u003e\nRegulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone\u003cbr\u003e\nGene ID: 15978\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nClone: XMG1.2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003cbr\u003e\nQ: How stable is PerCP\/Cyanine5.5 tandem as compared to PerCP alone?\u003cbr\u003e\nA: PerCP\/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864099999913,"sku":"505822","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-505822","provider":"Iright","version":"1.0","type":"link"}